ClinicalTrials.gg
Not yet recruitingNCT07495930Updated Apr 1, 2026

Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX319 Compared With EU-Phesgo®

A Phase 1 interventional study of HLX319 and EU-Phesgo in Health Adult Subjects, sponsored by Shanghai Henlius Biotech. Not yet recruiting at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-01.

Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

The study is being conducted to compare the pharmacokinetic (PK) parameters of HLX319 and EU-Phesgo® after a single subcutaneous administration in healthy male subjects in China, providing a basis for the design of subsequent clinical study protocols.

02

Conditions studied

  • Health Adult Subjects
03

In context

Lead sponsor

Shanghai Henlius Biotech is the lead sponsor of 133 studies on the registry; 57 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male subjects aged ≥18 and ≤45 years;
  2. The skin at the injection site is intact, without damage, tattoos, or other markings;
  3. Subjects have no history of disease or past medical history abnormalities that, in the judgment of the study physician, would affect the trial;
  4. Physical examination, vital signs, chest x-ray, , and laboratory investigations are normal or show abnormalities without clinical significance.
  5. Body weight (BW) ≥50 and ≤75 kg;
  6. (BMI) ≥19 and ≤24 kg/m² [BMI = weight (kg) / height² (m²)];
  7. Within 14 days prior to random allocation, (LVEF) assessed by echocardiography is within the normal range (≥55%);

Exclusion criteria

Exclusion Criteria:

  1. diseases including but not limited to the gastrointestinal tract, kidneys, liver, nerves, blood, endocrine system, tumors, respiratory system, immune system, mental health, and cardiovascular and cerebrovascular diseases;
  2. History of allergy or reactions.
  3. Intake of prescription drugs, over-the-counter drugs, or traditional Chinese medicine within 28 days prior to randomization;
  4. History of blood donation or blood loss (>450mL) within 3 months prior to randomization;
  5. Positive test results for Surface Antigen (HbsAg), Virus (HCV) antibodies, and (HIV) antibodies, or abnormal and clinically significant quantitative test results for syphilis spirochetes as determined by the sub investigator;
  6. History of upper respiratory tract infection or other acute infections within 2 weeks prior to r randomization;
  7. History of drug abuse, substance use;
  8. History of alcoholism or positive alcohol test results;

11. History of long-term heavy smoking .

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    HLX319 arm

    subjects will receive a single subcutaneous injection of HLX319.

    Drug: HLX319

  • Active comparator
    Eu-Phesgo arm

    subjects will receive a single subcutaneous injection of Eu-Phesgo.

    Drug: EU-Phesgo

Interventions

  • DrugHLX319

    HLX319 is a biosimilar of pertuzumab-trastuzumab monoclonal antibody injection (subcutaneous injection).

  • DrugEU-Phesgo

    EU-Phesgo is an original marketed drug product, with the generic name pertuzumab-trastuzumab monoclonal antibody injection (subcutaneous injection).

This study also gives Trastuzumab, Pertuzumab. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. AUC0-inf

    Area-under-curve of blood drug concentration-time from time 0 to infinity after a single drug administration

    Time frame: up to 85 days

  2. Cmax

    Peak concentration after a single administration

    Time frame: up to 85 days

Secondary outcomes

  1. AUC0-t

    Area-under-curve of the blood drug concentration-time curve from time zero to the last quantifiable concentration time

    Time frame: up to 85 days

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2026; primary completion for Jul 2026, 2 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2026
First posted
Mar 27, 2026
StartEst.
Apr 30, 2026
Primary completionEst.
Jul 1, 2026
CompletionEst.
Oct 10, 2026
Last update
Apr 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07495930
Responsible party
Sponsor
First posted
Mar 27, 2026
Start date
Apr 30, 2026 (estimated)
Primary completion
Jul 1, 2026 (estimated)
Completion
Oct 10, 2026 (estimated)
Last update
Apr 1, 2026

Study contacts

qi Jin
Contact
Qi_jin@henlius.com
86 159 5516 0489

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab

Start the discussion